Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

1.390 -0.240 (-14.72%)
Streaming Delayed Price Updated: 10:18 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeuroSense Therapeutics Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating. 
Via Benzinga
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Via Benzinga
NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
Groundbreaking ALS Therapy Shows Remarkable Survival Benefits as NeuroSense Continues to Advance Toward Potential Partnership with Pharma Giant (NASDAQ: NRSN)* 
Via News Direct
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
From Market News Alerts
Via Business Wire
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Bullish Wall Street Analyst Sees NeuroSense as a potential multibagger giving it a Buy Rating and $7.50 Price Target Representing a Significant Premium Over Current Prices; 
Via News Direct
Topics Regulatory Compliance
Exposures Legal Regulatory
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
From PESG Research
Via Business Wire
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment. 
Via Benzinga
Exposures Product Safety
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market 
Via News Direct
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
NeuroSense Therapeutics is in advanced talks with major pharmaceutical companies for a strategic partnership to develop and commercialize its ALS drug, PrimeC. The company expects to receive terms by... 
Via Benzinga
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024
NRSN stock results show that NeuroSense Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
NRSN stock results show that NeuroSense Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and... 
Via Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
US Stocks Higher; Private Payrolls Rise By 103,000 In November
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Shares of SentinelOne, Inc. (NYSE: S) rose sharply in pre-market trading after the company reported stronger-than-expected results for its third quarter and raised its annual revenue outlook. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning! 
Via InvestorPlace
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Via ACCESSWIRE
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday. 
Via Benzinga
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets. 
Via Benzinga
Dow Drops 50 Points; Netflix Sales Top Estimates
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 50 points on Friday. 
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.